Evidence map›Paper›PMID 34261137›Full record

ReviewSeminars in liver disease2021

Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review.

Xinpei Gu, Qin Lu, Chengcheng Zhang, Zhewei Tang, Liuxi Chu

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in liver disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. [Expert consensus on the clinical application of gut microbiota transplant therapy in chronic liver disease (version 2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  8. Scutellarin Alleviates CClInternational journal of molecular sciences · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease.Journal of clinical and translational hepatology · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Xinpei GuDepartment of Human Anatomy, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, China.
Qin LuDepartment of Prescription Science, School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang, China.
Chengcheng ZhangDepartment of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhewei TangDepartment of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Liuxi ChuInstitute of Child Development and Education, School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, China.
Hebei University of Chinese Medicine · CNShandong First Medical University · CNShanghai University of Traditional Chinese Medicine · CNShuguang Hospital · CNSoutheast University · CN

Funding

202014432203 College Student Innovation Funds Project for the Hebei University of Chinese Medicine2242019s10024 Fundamental Research Funds for the Southeast University31800952 College Student Innovation Funds Project for the Hebei University of Chinese Medicine3218006405 Fundamental Research Funds for the Southeast University81904129 National Natural Science Foundation of China
6 · The paper itself

Abstract

The human gut harbors a dense and highly diverse microbiota of approximately 1,000 bacterial species. The interaction between the host and gut bacteria strongly influences human health. Numerous evidence suggest that intestinal flora imbalance is closely associated with the development and treatment of liver diseases, including acute liver injury and chronic liver diseases (cirrhosis, autoimmune liver disease, and fatty liver). Therefore, regulating the gut microbiota is expected to be a new method for the adjuvant treatment of liver diseases. Fecal microbiota transplantation (FMT) is defined as the transplantation of gut microbiota from healthy donors to sick patients via the upper or lower gastrointestinal route to restore the normal intestinal balance. In this study, we briefly review the current research on the gut microbiota and its link to liver diseases and then summarize the evidence to elucidate the clinical application and development of FMT in liver disease treatment.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaFecal Microbiota TransplantationFecesHumansLiver Cirrhosis

Identifiers

PMID34261137
PMCPMC8492191
OpenAlexW3180682248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.